These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 12407324

  • 1. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
    Reginster JY.
    J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
    [Abstract] [Full Text] [Related]

  • 2. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
    Lippuner K, Haenggi W, Birkhaeuser MH, Casez JP, Jaeger P.
    J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
    [Abstract] [Full Text] [Related]

  • 3. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis--8 years follow-up.
    Prelevic GM, Markou A, Arnold A, Bartram C, Puzigaca Z, Ginsburg J.
    Maturitas; 2004 Mar 15; 47(3):229-34. PubMed ID: 15036493
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Hormone replacement therapy and its derivatives in the prevention and treatment of osteoporosis].
    Lamy O, Krieg MA.
    Rev Med Suisse Romande; 2002 Aug 15; 122(8):377-81. PubMed ID: 12357730
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
    Ziaei S, Moghasemi M, Faghihzadeh S.
    Climacteric; 2010 Apr 15; 13(2):147-56. PubMed ID: 19731119
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tibolone and osteoporosis.
    Lazovic G, Radivojevic U, Milosevic V, Lazovic A, Jeremic K, Glisic A.
    Arch Gynecol Obstet; 2007 Dec 15; 276(6):577-81. PubMed ID: 17605023
    [Abstract] [Full Text] [Related]

  • 14. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E, Wehren LE, Siris ES, Miller P, Chen YT, Abbott TA, Berger ML, Santora AC, Sherwood LM.
    Menopause; 2003 Dec 15; 10(5):412-9. PubMed ID: 14501602
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A.
    Ann Acad Med Stetin; 2003 Dec 15; 49():111-30. PubMed ID: 15552843
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW, Gluck OS, Lang E, Rakov V.
    Menopause; 2005 Dec 15; 12(6):741-8. PubMed ID: 16278618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.